Quest Diagnostics Stock - Analyst targets, sector review and weekly recap
19.06.2026 - 18:09:41 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 16:00 UTC. Details in the imprint.
Quest Diagnostics (US74834L1008) sits in a mature corner of US healthcare, where steady cash flows matter as much as growth stories. This Friday, the focus is on how the stock lines up against diagnostics peers and on the analyst targets that frame expectations.
All news and background on Quest Diagnostics stock
Price data, earnings reports and sector context for Quest Diagnostics stock are bundled on the topic page and in the company’s own investor relations material.
How the shares traded this week
Quest Diagnostics shares have traded in a relatively tight band around the mid-$190s in recent sessions, with MarketBeat citing a close at $194.79 on 06/18/2026. Volumes stayed moderate and in line with normal daily turnover for the stock.
Data from Economic Times’ US stock overview show the shares around $195.00 in recent trading, implying only a modest week-on-week change for the company. That muted move stands against a broader healthcare space where individual names saw larger swings.
Positioning in the diagnostics peer group
Quest Diagnostics operates in the diagnostics and research industry, where it competes with large lab and testing providers in the US and globally. The sector has been shaped by post-pandemic normalization and ongoing demand for chronic-disease and oncology testing.
Compared with smaller specialty labs, Quest Diagnostics stock represents a large-cap, diversified exposure in this niche of the healthcare system. That status typically brings lower volatility but also more modest short-term price moves when sector sentiment shifts.
What analysts signal on Quest
Recent analyst commentary summarized on MarketBeat shows a spread of ratings from Hold to Buy for Quest Diagnostics shares, alongside a range of price targets framing upside and downside scenarios. The consensus points to a stable, cash-generative business rather than a high-growth outlier.
On balance, Wall Street focuses on volume growth in routine testing, mix shifts toward higher-value assays, and cost discipline. Dividend continuity and buyback capacity also feature prominently in research notes, given the company’s established cash-flow profile.
Friday sector review and weekly recap
This week, the wider diagnostics and research segment reflected broader healthcare market themes: investor interest in predictable earnings streams amid macro uncertainty, and selective appetite for innovation-led stories in genomics and precision medicine. Quest Diagnostics sits in the more defensive camp.
Against this backdrop, the stock’s comparatively small weekly move looks consistent. Peers with higher R&D leverage often showed sharper swings on single data or regulatory headlines, while Quest Diagnostics traded more in step with the Standard & Poor's 500 index’s healthcare components.
How the company makes money
Quest Diagnostics generates most of its revenue from clinical laboratory testing services, spanning routine blood tests, advanced diagnostics, and specialized panels ordered by physicians, hospitals and employers. The company also offers wellness screening programs and diagnostic information services to health plans.
Where the stock trades today
Quest Diagnostics stock (US74834L1008) trades on the New York Stock Exchange at about $195.00 as of 06/19/2026, 11:30 AM ET.
Key facts on Quest Diagnostics stock
- Company: Quest Diagnostics Incorporated
- ISIN: US74834L1008
- WKN: 929312
- Ticker: DGX
- Venue: NYSE
- Price (as of 06/19/2026, 11:30 AM ET): 195.00 USD
- Market cap: 21,900,000,000 USD (as of 06/19/2026)
- Sector / Industry: Health Care / Diagnostics & Research
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
